Who Will Win This Small Drug Market?: ISIS Pharmaceuticals, Inc. (ISIS), Sanofi SA (SNY)
From Insider Monkey - Free Hedge Fund and Insider Trading Data
January 31, 2013 - 12:46pm
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Sanofi SA (ADR) (NYSE:SNY) received Food and Drug Administration approval this week for homozygous familial hypercholesterolemia (HoFH) treatment Kynamro. HoFH is a rare genetic disease that causes severely high LDL levels that pose cardiac risks. The patient pool resembles a puddle and already contains a contender: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)‘s Juxtapid received [...]
Continue reading this article »Share This Article: